Insmed reaffirmed guidance. Insmed stock fell 4.71 percent

Published on 10/08/2026 at 17:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BRINSUPRI guidance is USD 1.25 billion to USD 1.40 billion. Insmed stock costs EUR 87.11 on October 8, 2026 after EUR 91.42, minus 4.71 percent.

Key points in brief

Insmed reaffirmed fiscal 2026 BRINSUPRI and ARIKAYCE revenue guidance on October 5, 2026.
Insmed stock was trading at EUR 87.11 at Lang & Schwarz on October 8, 2026, down 4.71 percent versus the prior close.
Second-quarter 2026 BRINSUPRI revenue reached USD 309.2 million, up 49 percent sequentially.
Insmed will report third-quarter 2026 results on October 29, 2026, while CFO Sara Bonstein is scheduled to step down on October 30.

INSM, US4576693075, Illustration mit AI erstellt.

Insmed (ISIN US4576693075) was trading at EUR 87.11 at Lang & Schwarz on October 8, 2026 at 4:46 p.m. CEST, down 4.71 percent versus the prior close of EUR 91.42. On October 5, 2026, Insmed reaffirmed fiscal 2026 revenue guidance while announcing that CFO Sara Bonstein will step down on October 30.

Guidance remains the central figure

The company reaffirmed BRINSUPRI revenue guidance of USD 1.25 billion to USD 1.40 billion for fiscal 2026 and ARIKAYCE guidance of USD 450 million to USD 470 million. The same release set October 29, 2026 for third-quarter results and said Bonstein would remain CFO through the reporting process.

The guidance follows a strong second quarter. Benzinga reported that BRINSUPRI generated USD 309.2 million in revenue in the second quarter of 2026, up 49 percent sequentially. ARIKAYCE generated USD 116.3 million in the same quarter, up 8 percent year over year.

What does the guidance mean for growth?

The second-quarter revenue mix makes BRINSUPRI the larger near-term growth driver, while ARIKAYCE remains a recurring commercial contributor. Insmed's quarterly financial statements show total revenue of USD 425.49 million in the second quarter of 2026, compared with USD 305.96 million in the first quarter, while net loss narrowed to USD 13.24 million from USD 163.56 million.

The transition adds a management event ahead of the next results date. The October 5 release said Insmed had raised more than USD 4.2 billion in capital during Bonstein's tenure and expects cash flow positivity in 2027, making execution and financing discipline important counterweights to the revenue growth narrative.

Three dated milestones frame the story

On September 16, 2026, Insmed said its annual community program involved more than 1,350 employees. On September 21, 2026, it said the FDA had granted priority review for an ARIKAYCE supplemental application, with a January 28, 2027 target action date. On October 5, 2026, it reaffirmed fiscal 2026 guidance of USD 1.25 billion to USD 1.40 billion for BRINSUPRI and USD 450 million to USD 470 million for ARIKAYCE, according to Insmed.

Two dates matter next

Insmed's next scheduled reporting date is October 29, 2026, when the company plans to publish third-quarter results and hold its earnings call. October 30, 2026 is the announced date for Bonstein's CFO departure.

Stock reprices ahead of results

On the Nasdaq, the primary-exchange quote was USD 97.08 on October 8, 2026 at 11:00 a.m. EDT, while the 52-week range was USD 90.39 to USD 212.75 and market capitalization was USD 21.0 billion. The separate euro quote at Lang & Schwarz stood at EUR 87.11, with the intraday decline measured against its EUR 91.42 prior close.

The further course of trading is shown by the continuously updated real-time quote of Insmed stock.